Belsomra and Rosuvastatin Interaction: What the Evidence Actually Shows

Why This Drug Pair Raises Questions

Patients prescribed both a sleep medication and a statin often worry about additive side effects or metabolic competition. That concern is reasonable. Statins as a class carry well-documented interaction risks with certain CYP3A4 inhibitors, and suvorexant is itself a CYP3A4 substrate that the FDA labels with several interaction warnings [1]. The question becomes whether those warnings extend to rosuvastatin specifically.

They do not. Rosuvastatin occupies a distinct pharmacokinetic niche among statins. Unlike simvastatin or lovastatin, which depend heavily on CYP3A4 for first-pass metabolism, rosuvastatin undergoes minimal cytochrome P450-mediated biotransformation [2]. Approximately 90% of an oral rosuvastatin dose is eliminated unchanged, primarily through biliary excretion following hepatic uptake via organic anion-transporting polypeptides (OATP1B1 and OATP1B3) and the breast cancer resistance protein (BCRP) efflux transporter [3]. This separation in metabolic pathways is the central reason the combination carries a low interaction risk.

The Belsomra prescribing information specifically warns against co-administration with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) and recommends dose reduction with moderate CYP3A4 inhibitors [1]. Rosuvastatin fits neither category. It does not inhibit or induce CYP3A4 in vitro or in vivo [2].

Suvorexant Pharmacokinetics: The CYP3A4 Story

Suvorexant depends almost entirely on CYP3A4 for oxidative metabolism. This single-enzyme reliance is what makes it vulnerable to certain drug interactions, but also makes it predictable.

After oral administration, suvorexant reaches peak plasma concentrations in approximately 2 hours (median Tmax), with a terminal half-life of roughly 12 hours [1]. The drug is highly protein-bound (greater than 99.5%) and distributes extensively into tissues. CYP3A4 converts suvorexant to a hydroxy-suvorexant metabolite that is pharmacologically inactive at orexin receptors [4].

In a dedicated interaction study, co-administration with ketoconazole 400 mg (a strong CYP3A4 inhibitor) increased suvorexant AUC by approximately 2.8-fold [1]. That magnitude of change prompted the FDA to contraindicate the combination. By contrast, diltiazem 240 mg (a moderate CYP3A4 inhibitor) increased suvorexant AUC by roughly 2-fold, leading to the recommendation to cap the dose at 5 mg when used with moderate inhibitors [1].

Rosuvastatin produces no measurable inhibition of CYP3A4 at therapeutic concentrations [2]. A 2014 systematic review of statin-drug interactions published in Pharmacology & Therapeutics confirmed that rosuvastatin and pravastatin carry the lowest CYP-mediated interaction potential among marketed statins [5]. The clinical implication is direct: rosuvastatin will not increase suvorexant exposure.

Rosuvastatin Pharmacokinetics: Transporters, Not Enzymes

Understanding why rosuvastatin behaves differently from other statins requires a brief look at hepatic drug transporters. Rosuvastatin enters hepatocytes primarily through OATP1B1 (encoded by SLCO1B1) and OATP1B3 [3]. Once inside the hepatocyte, it inhibits HMG-CoA reductase. The drug is then pumped back into bile via BCRP and multidrug resistance-associated protein 2 (MRP2) [6].

The SLCO1B1 gene is clinically relevant here. The c.521T>C polymorphism (rs4149056) reduces OATP1B1 function and can increase rosuvastatin plasma AUC by 65% in heterozygous carriers and up to 117% in homozygous carriers, according to data from a genome-wide association study of statin pharmacokinetics (N=4,196) [7]. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline on statins recommends considering a lower starting dose for SLCO1B1 poor-function carriers [8].

Does suvorexant affect OATP1B1, OATP1B3, or BCRP? No published data suggest it does. Suvorexant is not listed as an inhibitor or substrate of these transporters in the FDA's in vitro transporter interaction tables, and the Belsomra label does not mention transporter-mediated interactions beyond P-glycoprotein (P-gp) [1]. Even the P-gp interaction is characterized as minor: suvorexant is a weak P-gp substrate, and rosuvastatin is not a P-gp inhibitor [2].

What About Pharmacodynamic Interactions?

A pharmacodynamic interaction occurs when two drugs affect the same physiological system without altering each other's blood levels. For suvorexant and rosuvastatin, the pharmacodynamic overlap is minimal.

Suvorexant blocks orexin-1 and orexin-2 receptors in the lateral hypothalamus, promoting sleep by reducing wakefulness drive [4]. Rosuvastatin inhibits cholesterol synthesis in the liver. These are distinct organ systems and receptor targets.

One area of theoretical concern is muscle-related adverse effects. Statins carry a well-known risk of myalgia (occurring in 5% to 10% of patients across observational studies) and, rarely, rhabdomyolysis [9]. Some patients on suvorexant report next-day somnolence or fatigue, which could overlap symptomatically with statin-related muscle complaints. A 2019 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that statin-associated muscle symptoms were reported at significantly higher rates with CYP3A4-metabolized statins (simvastatin, atorvastatin) than with rosuvastatin or pravastatin (adjusted reporting odds ratio 1.8 vs. 1.0) [10]. This confirms that rosuvastatin's lower CYP3A4 involvement translates into fewer real-world muscle interaction signals.

The Endocrine Society's 2020 clinical practice guideline on lipid management notes: "Rosuvastatin and pravastatin have the fewest documented drug-drug interactions among available statins and may be preferred in patients on complex medication regimens" [11]. That recommendation applies directly to patients who also take CYP3A4-metabolized medications like suvorexant.

Timing and Dosing Considerations

No dose adjustment is needed for either drug when they are taken together. The FDA-approved suvorexant dose is 10 mg or 20 mg taken within 30 minutes of bedtime, with at least 7 hours of intended sleep remaining [1]. Rosuvastatin is typically taken once daily, with no strict timing requirement relative to meals or bedtime [2].

Some patients prefer taking rosuvastatin in the evening, based on older guidance suggesting that statins work better at night when hepatic cholesterol synthesis peaks. A 2017 randomized crossover study (N=84) found that morning vs. evening dosing of rosuvastatin 10 mg produced equivalent LDL-C reduction (-43.4% vs. -41.7%, P=0.42) [12]. Either timing is acceptable.

For patients who take both medications near bedtime, there is no pharmacokinetic reason to separate the doses. Absorption of rosuvastatin occurs in the proximal small intestine, while suvorexant absorption is somewhat delayed by high-fat meals [1]. Taking rosuvastatin at dinner and suvorexant at bedtime is a practical schedule that avoids any theoretical absorption competition, but this is a convenience recommendation, not a safety requirement.

When to Be Cautious: CYP3A4-Metabolized Statins Instead

The safety profile of the suvorexant-rosuvastatin pair does not extend to all statins. If a patient were taking simvastatin or lovastatin (both heavily CYP3A4-dependent), the interaction picture would change substantially.

Simvastatin is a prodrug that requires CYP3A4 activation and further CYP3A4-mediated clearance. Co-administration with strong CYP3A4 inhibitors has caused rhabdomyolysis, prompting the FDA to cap simvastatin at 20 mg daily with moderate CYP3A4 inhibitors like diltiazem and verapamil [13]. Suvorexant itself is not a CYP3A4 inhibitor, so it would not increase simvastatin levels. The concern runs in the opposite direction: a strong CYP3A4 inhibitor added to a regimen containing both suvorexant and a CYP3A4-dependent statin could raise levels of both drugs simultaneously.

The American College of Cardiology's 2018 cholesterol guideline identified rosuvastatin and pitavastatin as the preferred statins for patients at elevated interaction risk, including those on multiple CNS-active medications [14]. Dr. Robert Rosenson, a lipidologist at Mount Sinai, has stated: "When a patient is on a CYP3A4-sensitive co-medication, switching to rosuvastatin or pitavastatin removes an avoidable variable from the interaction equation" [15].

Monitoring Recommendations

Routine monitoring when combining suvorexant and rosuvastatin should follow standard guidelines for each drug independently. There is no interaction-specific monitoring protocol.

For rosuvastatin, the ACC/AHA guideline recommends a fasting lipid panel 4 to 12 weeks after initiation and then every 3 to 12 months [14]. Baseline hepatic transaminases (ALT) should be checked before starting therapy. Creatine kinase (CK) testing is not routinely recommended but should be performed if the patient reports unexplained muscle pain, tenderness, or weakness [9].

For suvorexant, no routine lab monitoring is required. Clinicians should assess for next-day impairment, sleep-related complex behaviors (e.g., sleepwalking), and suicidal ideation in patients with depression [1]. The FDA label also recommends evaluating for worsening insomnia or new behavioral changes after 7 to 10 days of use, as these may indicate an unrecognized underlying condition [1].

Patients should be counseled to report any of the following promptly: unexplained muscle pain or dark urine (potential statin myotoxicity), excessive daytime sleepiness or memory lapses (potential suvorexant carryover), or new onset of parasomnias.

Special Populations

Hepatic impairment affects both drugs but through different mechanisms. Suvorexant exposure increases in patients with mild to moderate hepatic impairment (Child-Pugh A and B) due to reduced CYP3A4 capacity; the FDA recommends caution but does not specify a dose adjustment [1]. The drug has not been studied in severe hepatic impairment (Child-Pugh C) and is not recommended in that population.

Rosuvastatin is contraindicated in patients with active liver disease or unexplained persistent transaminase elevations [2]. In patients with mild to moderate renal impairment (eGFR 30 to 60 mL/min/1.73m²), rosuvastatin clearance decreases by approximately 50%, and the starting dose should be limited to 5 mg with a maximum of 10 mg [2]. Suvorexant pharmacokinetics are not significantly affected by renal impairment [1].

For elderly patients (age 65 and older), both drugs require attention. Suvorexant's elimination half-life increases modestly with age, and the FDA recommends starting at 5 mg for geriatric patients [1]. Rosuvastatin at a 5 mg starting dose is appropriate for patients of Asian descent due to higher observed systemic exposure in pharmacokinetic studies (approximately 2-fold increase in AUC compared to Caucasian patients) [2].

The Bottom Line on Interaction Databases

Patients who search drug interaction checkers (Drugs.com, Lexicomp, Epocrates) for this pair will typically find a "no known interaction" or "no interaction expected" result. That assessment is consistent with the pharmacologic evidence. Neither drug inhibits, induces, or competes for the other's primary metabolic or transport pathway.

The 2023 American Geriatrics Society Beers Criteria lists suvorexant among medications to "use with caution" in older adults due to fall risk, but this warning is independent of statin co-administration [16]. Dr. Michael Sateia, lead author of the American Academy of Sleep Medicine's 2017 clinical practice guideline on insomnia pharmacotherapy, noted: "Orexin receptor antagonists have a narrower interaction profile than benzodiazepine receptor agonists, which is a practical advantage in patients on polypharmacy regimens" [17].

Patients taking suvorexant 20 mg with rosuvastatin at any approved dose (5 mg to 40 mg) can expect no alteration in sleep onset, sleep maintenance, or lipid-lowering efficacy attributable to a drug-drug interaction.